Abstract
First-line treatment of non-small cell lung cancer (NSCLC) has undergone a paradigm shift to platinum combination chemotherapy together with an immune checkpoint inhibitor. In addition, such chemotherapy plus nivolumab (antibody to PD-1) and ipilimumab (antibody to cytotoxic T lymphocyte-associated protein-4) prolonged survival in advanced NSCLC patients compared with chemotherapy alone. It is expected as a treatment aiming for long-term survival. The differences in the positioning of immunotherapy for NSCLC from other cancer types are as follows: (1) In patients with positive driver gene alteration such as EGFR gene mutation or ALK translocation, anti-PD-(L)1 antibody alone is ineffective, and (2) The positioning of anti-CTLA-4 antibody has not yet been determined.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
